Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
Authors:
- Giancarlo ComiGCGiancarlo Comi
- Nicola De StefanoNSNicola De Stefano
- Mark S FreedmanMFMark S Freedman
- Frederik BarkhofFBFrederik Barkhof
- Chris H PolmanCPChris H Polman
- Florence Casset-SemanazFCFlorence Casset-Semanaz
- Brian HennessyBHBrian Hennessy
- Bettina StubinskiBSBettina Stubinski
- Ludwig KapposLKLudwig Kappos
- 5 December 2011
- journal article
- Published by Elsevier in The Lancet Neurology
- Vol. 11 (1) , 33-41